CSBR
Price
$9.78
Change
-$0.17 (-1.71%)
Updated
Jan 17 closing price
Capitalization
133.98M
58 days until earnings call
SCNI
Price
$3.51
Change
-$0.06 (-1.68%)
Updated
Jan 17 closing price
Capitalization
2.99M
Ad is loading...

CSBR vs SCNI

Header iconCSBR vs SCNI Comparison
Open Charts CSBR vs SCNIBanner chart's image
Champions Oncology
Price$9.78
Change-$0.17 (-1.71%)
Volume$30.53K
Capitalization133.98M
Scinai Immunotherapeutics
Price$3.51
Change-$0.06 (-1.68%)
Volume$4.85K
Capitalization2.99M
CSBR vs SCNI Comparison Chart
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCNI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSBR vs. SCNI commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Hold and SCNI is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CSBR: $9.78 vs. SCNI: $3.51)
Brand notoriety: CSBR and SCNI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 53% vs. SCNI: 46%
Market capitalization -- CSBR: $133.98M vs. SCNI: $2.99M
CSBR [@Biotechnology] is valued at $133.98M. SCNI’s [@Biotechnology] market capitalization is $2.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 0 FA rating(s) are green whileSCNI’s FA Score has 2 green FA rating(s).

  • CSBR’s FA Score: 0 green, 5 red.
  • SCNI’s FA Score: 2 green, 3 red.
According to our system of comparison, SCNI is a better buy in the long-term than CSBR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 3 TA indicator(s) are bullish while SCNI’s TA Score has 5 bullish TA indicator(s).

  • CSBR’s TA Score: 3 bullish, 4 bearish.
  • SCNI’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SCNI is a better buy in the short-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а +3.27% price change this week, while SCNI (@Biotechnology) price change was -0.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CSBR is expected to report earnings on Mar 18, 2025.

SCNI is expected to report earnings on May 02, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSBR($134M) has a higher market cap than SCNI($2.99M). CSBR YTD gains are higher at: 14.119 vs. SCNI (4.933). SCNI has higher annual earnings (EBITDA): 7.8M vs. CSBR (1.43M). CSBR has more cash in the bank: 2.75M vs. SCNI (1.03M). SCNI has less debt than CSBR: SCNI (1.23M) vs CSBR (6.78M). CSBR has higher revenues than SCNI: CSBR (53.6M) vs SCNI (452K).
CSBRSCNICSBR / SCNI
Capitalization134M2.99M4,476%
EBITDA1.43M7.8M18%
Gain YTD14.1194.933286%
P/E RatioN/A1.46-
Revenue53.6M452K11,858%
Total Cash2.75M1.03M267%
Total Debt6.78M1.23M552%
FUNDAMENTALS RATINGS
CSBR vs SCNI: Fundamental Ratings
CSBR
SCNI
OUTLOOK RATING
1..100
8614
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
998
PRICE GROWTH RATING
1..100
3561
P/E GROWTH RATING
1..100
4655
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCNI's Valuation (24) in the Pharmaceuticals Major industry is significantly better than the same rating for CSBR (98) in the Biotechnology industry. This means that SCNI’s stock grew significantly faster than CSBR’s over the last 12 months.

CSBR's Profit vs Risk Rating (77) in the Biotechnology industry is in the same range as SCNI (100) in the Pharmaceuticals Major industry. This means that CSBR’s stock grew similarly to SCNI’s over the last 12 months.

SCNI's SMR Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for CSBR (99) in the Biotechnology industry. This means that SCNI’s stock grew significantly faster than CSBR’s over the last 12 months.

CSBR's Price Growth Rating (35) in the Biotechnology industry is in the same range as SCNI (61) in the Pharmaceuticals Major industry. This means that CSBR’s stock grew similarly to SCNI’s over the last 12 months.

CSBR's P/E Growth Rating (46) in the Biotechnology industry is in the same range as SCNI (55) in the Pharmaceuticals Major industry. This means that CSBR’s stock grew similarly to SCNI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRSCNI
RSI
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 12 days ago
83%
Momentum
ODDS (%)
N/A
Bullish Trend 12 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 12 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
72%
Bullish Trend 12 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
76%
Bullish Trend 12 days ago
78%
Advances
ODDS (%)
Bullish Trend 21 days ago
75%
Bullish Trend 14 days ago
78%
Declines
ODDS (%)
Bearish Trend 18 days ago
79%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
85%
Aroon
ODDS (%)
Bullish Trend 12 days ago
75%
N/A
View a ticker or compare two or three
Ad is loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCNI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MPLN16.071.23
+8.29%
MultiPlan Corporation
GNSS2.920.03
+1.04%
Genasys
SNEX105.010.78
+0.75%
StoneX Group
QGEN46.000.10
+0.22%
Qiagen NV
LXEH4.92-0.43
-8.12%
Lixiang Education Holding Co Ltd

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
-1.71%
SYRE - CSBR
32%
Poorly correlated
+0.34%
SCNI - CSBR
27%
Poorly correlated
-1.54%
OABI - CSBR
25%
Poorly correlated
+0.94%
PLUR - CSBR
24%
Poorly correlated
-2.48%
BLPH - CSBR
23%
Poorly correlated
N/A
More

SCNI and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCNI has been closely correlated with SNPX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if SCNI jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCNI
1D Price
Change %
SCNI100%
-1.54%
SNPX - SCNI
73%
Closely correlated
N/A
ACHL - SCNI
45%
Loosely correlated
-0.87%
SYRE - SCNI
43%
Loosely correlated
+0.34%
MBIO - SCNI
37%
Loosely correlated
-5.61%
BIVI - SCNI
34%
Loosely correlated
+0.45%
More